2019 American Transplant Congress
Bcl-2/Bcl-xL Inhibition by Navitoclax vs. Bcl-2 Alone Inhibition by Venetoclax for Induction of Mixed Chimerism in Non-Human Primates
*Purpose: We recently demonstrated that a specific Bcl-2 inhibitor, Venetoclax, can promote mixed chimerism and renal allograft tolerance in non-human primates (NHPs) with reduced myelosuppressive…2019 American Transplant Congress
Donor-Specific Tregs Prolong Peripheral Chimerism in Baboons Receiving GalTKO hCD47-tg Porcine Peripheral Blood Stem Cells
*Purpose: We have previously evaluated the ability of transplantation of polyclonal expanded recipient T regulatory cells to prolong xenogeneic chimerism and skin grafts after transplantation…2019 American Transplant Congress
Bcl-2 Inhibition with Venetoclax Promotes Induction of Mixed Chimerism and Renal Allograft Tolerance without Severe Myelosuppression in Non-Human Primate
*Purpose: Specific Bcl-2 inhibition has been shown to promote mixed chimerism and skin allograft tolerance without myelosuppressive conditioning in murine models. To extend this approach…2018 American Transplant Congress
Enhancement of Intrinsic Apoptosis via Bcl-2 Inhibition Promotes Induction of Robust Mixed Chimerism and Renal Allograft Tolerance without Myelosuppression in Nonhuman Primates
Background: Successful induction of mixed chimerism (MC) and renal allograft tolerance has been achieved in both nonhuman primate (NHP) and man following conditioning that included…2018 American Transplant Congress
Robust Hematopoietic Mixed Chimerism and Donor-Specific Skin Allograft Tolerance after Non-Genotoxic Anti-CD117 Immunotoxin Conditioning and Donor Bone Marrow Allotransplantation
Establishing hematopoietic chimerism enables donor-specific allograft tolerance; however, chimerism protocols typically require either genotoxic conditioning or mega-doses of donor bone marrow cells (BMC), impeding clinical…2018 American Transplant Congress
PD-L1 May Serve as a Biomarker for Chimerism-Induced Tolerance in Kidney Transplant Recipients
1University of Louisville, Louisville, KY; 2Northwestern Memorial Hospital, Chicago, IL.
Durable chimerism is currently the most reliable biomarker of donor specific tolerance. Identifying and validating other predictive biomarkers is therefore a high priority. Since 2009…2018 American Transplant Congress
Non-Myeloablative Conditioning with Low-Dose Total Body Irradiation in Place of Cyclophosphamide Induces Mixed Chimerism and Long-Term Immunosuppression Free Allograft Survival without Acute Kidney Injury in HLA Mismatched Kidney Transplantation
We have achieved successful induction of long-term immunosuppression (IS) free renal allograft survival in HLA mismatched kidney transplantation using cyclophosphamide (CP) based conditioning and combined…2018 American Transplant Congress
Immunity and Tolerance after Bilateral Orthotopic Lung Transplant (BOLT) in Tandem with a CD3+/CD19+ Depleted Vertebral Bone Marrow Transplant (BOLT+BMT) from 1 of 8 HLA-Matched Cadaveric Donors
Primary immunodeficiency patients may develop pulmonary complications and most are ineligible for either lung transplant or BMT due to futility. We report our first 2…2018 American Transplant Congress
Absolute Quantification of Plasma Graft-Derived Cell-Free DNA for Diagnosis of Kidney Transplant Rejection
Aim: To study the performance of droplet digital PCR absolute measurement of graft-derived cell-free DNA (gdcfDNA) for the diagnosis of kidney allograft rejection.Methods: Homozygous deletion…2018 American Transplant Congress
A Novel Conditioning Approach to Establish Chimerism Using Manipulation of JAK-STAT Pathways
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY.
Hematopoietic chimerism establishes donor-specific tolerance to solid organ allografts. Targeting recipient immune cells (T, NK cells and macrophages) can effectively reduce the dose of total…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »